Incyte CorporationINCY and its partner Eli Lilly and Company LLY announced encouraging top line data from the third phase III study RA BEGIN evaluating the safety and efficacy of baricitinib in patients with moderately to severely active rheumatoid arthritis
Incyte & Eli Lilly Post Positive Phase III Data on Baricitinib
